Guide

Pharmaceutical GMP readiness in the European Union

The EU pharma framework is set by Directive 2001/83/EC (human medicines) and Directive 2001/82/EC (veterinary), implemented by EudraLex Volume 4 (EU GMP). EMA coordinates centrally authorized products; national competent authorities (BfArM, ANSM, AEMPS, AIFA, etc.) issue manufacturing/import authorizations (MIA) and inspect sites. Every batch placed on the EU market must be certified by a Qualified Person under Annex 16. Distribution follows EU GDP (2013/C 343/01). Serialization follows the Falsified Medicines Directive (FMD) with the EMVS hub. This guide covers the EU layer over an ICH Q10 PQS.

Start free trial Free trial, no credit card, onboard in days, not months.

Regulator and legal basis

EU GMP is published as EudraLex Volume 4: Part I (finished products), Part II (APIs — mirrors ICH Q7), and Annexes. Critical annexes: Annex 1 (sterile, 2022 revision in force), Annex 11 (computerised systems), Annex 15 (qualification and validation), Annex 16 (QP certification and batch release), Annex 13 (IMPs). National competent authorities issue the MIA and conduct inspections; outcomes are published in EudraGMDP.

Qualified Person and batch release

Every batch — manufactured in or imported into the EU/EEA — must be certified by a named QP per Annex 16 before release for sale. The QP confirms manufacture, testing, and supply-chain compliance, including any third-country API source under written confirmation. The QP is personally accountable; the role cannot be delegated.

EU GDP and FMD serialization

EU GDP applies from MIA holder through wholesale to dispensing pharmacy: temperature mapping, qualified suppliers/customers, returns, recalls, falsified medicines reporting. FMD requires a unique identifier (2D Datamatrix with product code, serial, batch, expiry) and tamper-evidence on most prescription medicines, verified against the European Medicines Verification System at dispense.

Inspection style and common findings

EU/PIC/S inspections classify findings as critical, major, or other; outcomes are recorded as GMP certificates or non-compliance reports in EudraGMDP. Recurring themes: Annex 1 contamination control strategy gaps, data integrity (PIC/S PI 041 / ALCOA+), supplier oversight of APIs, and CAPA effectiveness. A non-compliance report can trigger product recall and MIA suspension.

A 90–180 day EU readiness path

Days 0–30: appoint QPs (per site and per product flow), confirm MIA scope, map products to Annexes. Days 31–90: close Annex 1 contamination control strategy gaps; align Annex 11 / GAMP 5 controls; verify FMD onboarding to the national medicines verification organization. Days 91–180: run mock inspection against EudraLex Vol 4, request inspection by the supervisory authority, and obtain or renew the GMP certificate.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

QP release

QP release means a Qualified Person must personally certify each batch complies with its authorisation and GMP before it can be supplied in the EU or UK.

EU GDP

EU GDP defines how medicines must be stored, handled, and transported so quality and authenticity are preserved from manufacturer to pharmacy, with licensed wholesalers and brokers operating under a robust quality system.

EU GMP Annex 1 Sterile

Annex 1 sets the modern, risk-based standard for sterile manufacturing, requiring a holistic contamination control strategy, robust aseptic operations, and documented evidence that facilities and processes consistently protect patients.

EU Annex 11

Annex 11 defines how GMP computerized systems must be validated, controlled, and monitored to protect product quality and patient safety across the EU, with strong data integrity and lifecycle expectations.

Annex 15

Annex 15 defines EU expectations for risk-based qualification and validation across facilities, equipment, processes, cleaning, and computerized systems with lifecycle evidence and robust change control.

GAMP 5

GAMP 5 Second Edition shows how to right-size validation for modern, cloud and agile software while meeting Annex 11 and Part 11 expectations without drowning teams in documents.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Document control

Versioned SOPs, controlled artwork, periodic review with e-signatures.

QMS

CAPA, deviations, change control, management review wired together.

Audits & CAPA

Findings auto-route to owners with statutory clocks and evidence trail.

Industries this hits hardest

Frequently asked

Can one QP cover multiple sites?

Yes if listed on each MIA and physically able to discharge the duty. Most multi-site networks appoint a primary QP per site plus deputies; one QP must certify each specific batch.

How does Annex 16 handle imported drugs?

The EU QP must certify every imported batch; full testing in the EU is required unless a written confirmation or MRA waiver applies (e.g., EU–US, EU–Switzerland, EU–Japan). The QP retains accountability regardless of MRA.

Does Brexit affect EU supply?

Yes. Goods released by a UK QP are no longer automatically valid for the EU/EEA. EU importers must hold an MIA(IMP)/MIA and an EU QP must re-certify, unless covered under the Northern Ireland Windsor Framework arrangements.

What is the most common Annex 1 inspection finding?

Missing or incomplete Contamination Control Strategy (CCS) — the 2022 revision made the CCS a documented, holistic, and reviewed artifact. Environmental monitoring trending and aseptic process simulation justification are the next two.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →